NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the safety of NovoTTF-100A in combination with bevacizumab and
carmustine and to see how well they work in treating patients with glioblastoma multiforme
that has returned for the first time. NovoTTF-100A, a type of electric field therapy,
delivers low intensity, alternating "wave-like" electric fields that may interfere with
multiplication of the glioblastoma multiforme cells. Monoclonal antibodies, such as
bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as carmustine, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving NovoTTF-100A together with bevacizumab and carmustine may be an effective
treatment for glioblastoma multiforme.